Characterization of the molecular determinants of primary HIV-1 Vpr proteins: Impact of the Q65R and R77Q substitutions on Vpr functions

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Jacquot, Guillaume ^a,b   Le Rouzic, Erwann ^a,b   Maidou Peindara, Priscilla ^a,b   Maizy, Marion ^a,b   Lefrère, Jean Jacques ^c   Daneluzzi, Vincent ^a,b   Monteiro Filho, Carlos M R ^d   Hong, Duanping ^d   Planelles, Vicente ^d   Morand Joubert, Laurence ^e   Benichou, Serge ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

UBIQUITIN PROTEIN LIGASE E3; VPR PROTEIN; UBIQUITIN PROTEIN LIGASE; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; VIRUS CELL INTERACTION; BIOLOGICAL MODEL; CYTOLOGY; GENETIC VARIABILITY; GENETICS; LONG TERMINAL REPEAT; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; MUTATION; REGULATOR GENE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELES; AMINO ACID SEQUENCE; APOPTOSIS; GENE PRODUCTS, VPR; GENES, VPR; GENETIC VARIATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; TERMINAL REPEAT SEQUENCES; UBIQUITIN-PROTEIN LIGASES; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70449379633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007514     Document Type: Article

References (48)

1. Le Rouzic E, Benichou S (2005) The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2: 11.
2. Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, et al. (1995) Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 69: 2378-2383.
3. Lang SM, Weeger M, Stahl-Hennig C, Coulibaly C, Hunsmann G, et al. (1993) Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 67: 902-912.
4. Selig L, Benichou S, Rogel ME, Wu LI, Vodicka MA, et al. (1997) Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J Virol 71: 4842-4846.
5. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol 74: 7039-7047.
6. Chen R, Le Rouzic E, Kearney JA, Mansky LM, Benichou S (2004) Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate thevirus mutation rate and for replication in macrophages. J Biol Chem.
7. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M (1998) Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 273: 13347-13352.
8. Fouchier RA, Meyer BE, Simon JH, Fischer U, Albright AV, et al. (1998) Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol 72: 6004-6013.
9. Le Rouzic E, Mousnier A, Rustum C, Stutz F, Hallberg E, et al. (2002) Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 277: 45091-45098.
10. Vodicka MA, Koepp DM, Silver PA, Emerman M (1998) HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 12: 175-185.
11. Nitahara-Kasahara Y, Kamata M, Yamamoto T, Zhang X, Miyamoto Y, et al. (2007) A novel nuclear import of Vpr promoted by importin {alpha} is crucial for HIV-1 replication in macrophages. J Virol;JVI.01928-01906.
12. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, et al. (2007) HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4A(VPRBP) E3 Ubiquitin Ligase. PLoS Pathog 3: e85.
13. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, et al. (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4: 57.
14. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, et al. (2007) Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 104: 11778-11783.
15. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, et al. (2007) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6: 182-188.
16. Tan L, Ehrlich E, Yu XF (2007) DDB1 and Cul4A are required for HIV-1 Vpr-induced G2 arrest. J Virol.
17. Wen X, Duus KM, Friedrich TD, de Noronha CM (2007) The HIV1 protein VPR acts to promote G2 cell cycle arrest by engaging a DDB1 and cullin4A containing ubiquitin ligase complex using VPRBP/DCAF1 as an adaptor. J Biol Chem.
18. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, et al. (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4: 65-71.
19. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR (1995) Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 69: 7909-7916.
20. Chen M, Elder RT, Yu M, O'Gorman MG, Selig L, et al. (1999) Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. J Virol 73: 3236-3245.
21. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, et al. (1995) Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 69: 7032-7044.
22. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, et al. (2003) Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 111: 1547-1554.
23. Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, et al. (2006) Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. Aids 20: 567-574.
24. Fischer A, Lejczak C, Lambert C, Roman F, Servais J, et al. (2004) Is the Vpr R77Q mutation associated with long-term non-progression of HIV infection? Aids 18: 1346-1347.
25. Chiu YL, Greene WC (2007) The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements. Annu Rev Immunol.
26. Bell CM, Connell BJ, Capovilla A, Venter WD, Stevens WS, et al. (2007) Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res Hum Retroviruses 23: 322-330.
27. Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, et al. (2007) Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). Aids 21: 1043-1045.
28. Rajan D, Wildum S, Rucker E, Schindler M, Kirchhoff F (2006) Effect of R77Q, R77A and R80A changes in Vpr on HIV-1 replication and CD4 T cell depletion in human lymphoid tissue ex vivo. Aids 20: 831-836.
29. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005) Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79: 9006-9018.
30. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453-459.
31. Pantaleo G, Fauci AS (1996) Immunopathogenesis of HIV infection. Annu Rev Microbiol 50: 825-854.
32. Meier UC, Klenerman P, Griffin P, James W, Koppe B, et al. (1995) Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 270: 1360-1362.
33. Agostini I, Popov S, Hao T, Li JH, Dubrovsky L, et al. (2002) Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection. AIDS Res Hum Retroviruses 18: 283-288.
34. Zhou Y, Ratner L (2000) Phosphorylation of human immunodeficiency virus type 1 Vpr regulates cell cycle arrest. J Virol 74: 6520-6527.
35. Schrofelbauer B, Hakata Y, Landau NR (2007) HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A 104: 4130-4135.
36. Andersen JL, Planelles V (2005) The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 3: 43-51.
37. Andersen JL, Dehart JL, Zimmerman ES, Ardon O, Kim B, et al. (2006) HIV-1 Vpr-Induced Apoptosis Is Cell Cycle Dependent and Requires Bax but Not ANT. PLoS Pathog 2: e127.
38. Morellet N, Bouaziz S, Petitjean P, Roques BP (2003) NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol 327: 215-227.
39. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, et al. (2001) Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294: 1105-1108.
40. Nishizawa M, Kamata M, Mojin T, Nakai Y, Aida Y (2000) Induction of apoptosis by the Vpr protein of human immunodeficiency virus type 1 occurs independently of G(2) arrest of the cell cycle. Virology 276: 16-26.
41. Waldhuber MG, Bateson M, Tan J, Greenway AL, McPhee DA (2003) Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest despite nuclear membrane or nuclear localization. Virology 313: 91-104.
42. Lai M, Chen J (2006) The role of Vpr in HIV-1 disease progression is independent of its G2 arrest induction function. Cell Cycle 5: 2275-2280.
43. Jacquot G, le Rouzic E, David A, Mazzolini J, Bouchet J, et al. (2007) Localization of HIV-1 Vpr to the nuclear envelope: Impact on Vpr functions and virus replication in macrophages. Retrovirology 4: 84.
44. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB (1997) Nuclear import, virion incorporation, and cell cycle arrest/ differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 71: 6339-6347.
45. Lefrere JJ, Morand-Joubert L (2004) Non-progression of HIV infection 20 years after diagnosis. Transfusion 44: 623-624.
46. Lefrere JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, et al. (1997) Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 90: 1133-1140.
47. Selig L, Pages JC, Tanchou V, Preveral S, Berlioz-Torrent C, et al. (1999) Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 73: 592-600.
48. Py B, Slomianny C, Auberger P, Petit PX, Benichou S (2004) Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J Immunol 172: 4008-4017.